OLD Category: Oncology

Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells

• Simon N et al.,

Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth

• Messick T.E. et al.,

Differential Expression of Mitochondrial Biogenesis Markers in Mouse and Human SHH-Subtype Medulloblastoma

• Łastowska M. et al.,

DICER1 somatic mutations strongly impair miRNA processing even in benign thyroid lesions

• Poma A.M. et. al.,

Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion

• McEvoy C.R. et al.,

Phase I clinical trial of decitabine (5-aza-2′-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases

• Jansen Y.J.L. et. al.,

MicroRNA-Mediated Suppression of the TGF-? Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance

• Cornell L. et. al.,

Whole transcriptome targeted gene quantification provides new insights on pulmonary sarcomatoid carcinomas

• Alì G et al.,

Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms

• Stivala S. et al.,

Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptation

• Long JE et al.,

Cancer-associated acinar-to-ductal metaplasia within the invasive front of pancreatic cancer contributes to local invasion

• Kibe S. et al.,

Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers

• Chung V. et al.,